Jiang et al. observed that GRg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulating the EGFR/PI3K/Akt signaling pathway (Jiang et al., 2017). This evidence concerns the gene TLE3 and pancreatic neoplasm.